Welcome to our dedicated page for Cargo Therapeutics SEC filings (Ticker: CRGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical data tables, option-grant footnotes and sudden 8-K trial updates make <>Cargo Therapeutics (CRGX)<> filings some of the toughest reads in biotech. Finding the CD22 response rates or spotting a shelf registration that hints at future dilution can mean parsing hundreds of pages. Our platform delivers Cargo Therapeutics SEC filings explained simply, turning dense disclosures into clear, AI-generated summaries you can trust.
Every document posted to EDGAR is captured in real time and decoded by Stock Titan’s AI so you see what matters first. Need the Cargo Therapeutics quarterly earnings report 10-Q filing even though revenue is still years away? We tag the R&D burn rate, cash runway and milestone payments automatically. Curious about Cargo Therapeutics insider trading Form 4 transactions? Receive instant alerts on Cargo Therapeutics Form 4 insider transactions real-time and track each executive stock move. Our coverage spans:
- 10-K – Cargo Therapeutics annual report 10-K simplified with cash-runway and risk-factor highlights.
- 10-Q – Quarter-over-quarter trial spend and liquidity trends.
- 8-K – Cargo Therapeutics 8-K material events explained, from FDA meetings to manufacturing outages.
- Form 4 – Cargo Therapeutics executive stock transactions Form 4 distilled into buy/sell dashboards.
- DEF 14A – Cargo Therapeutics proxy statement executive compensation parsed for option grants and milestones.
Whether you’re monitoring trial milestones, calculating dilution risk, or seeking a quick Cargo Therapeutics earnings report filing analysis, our AI-powered summaries, side-by-side comparisons and keyword search help you cut research time from hours to minutes. Start understanding Cargo Therapeutics SEC documents with AI today and make better decisions with complete, timely information.
CARGO Therapeutics filed prospectus supplements on Form S-8 to register shares for employee equity plans. The filing registers a total of 15,070,259 shares across multiple prior Form S-8 registrations: 3,395,840 shares under the 2021 Stock Option and Grant Plan, 4,212,860 shares under the 2023 Incentive Award Plan, 386,725 shares under the Employee Stock Purchase Plan, plus additional registrations of 2,060,277 and 412,055 shares (Form S-8 No. 333-278160) and 2,302,126 shares (Form S-8 No. 333-285749). These registrations enable the company to issue shares to employees and service providers under its compensation plans.
CARGO Therapeutics, Inc. (CRGX) amended its shelf registration to cover a base prospectus authorizing up to $300,000,000 of securities, and separately registers the sale of up to $200,000,000 of common stock that may be sold under a sales agreement with TD Securities (USA) LLC (filed December 6, 2024). The filing also references a prior registration for the sale of up to 6,471,000 shares held by selling stockholders (filed June 17, 2024).
CARGO Therapeutics amended its previously filed Schedule 14D-9 to add a new subsection following the "Regulatory Approvals" section. The filing reiterates the terms of the pending tender offer by Concentra Biosciences, LLC to acquire all outstanding shares of CARGO common stock for $4.379 per share in cash plus one non-transferable contingent value right (CVR) per share. The Offer is governed by the Offer to Purchase dated July 21, 2025, and the related Letter of Transmittal, each as may be amended or supplemented. The amendment is signed by Anup Radhakrishnan in his capacity as Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer.
CARGO Therapeutics, Inc. Schedule 13G/A discloses that a group of affiliated investment entities led by Madison Avenue International LP and related parties beneficially own 4,193,626 shares of common stock, representing approximately 9.1% of the company's outstanding common stock based on 46,110,228 shares outstanding as of April 21, 2025. The ownership is reported as shared voting and shared dispositive power rather than sole control.
The filing identifies the reporting persons (Madison Avenue International LP; Madison Avenue Partners, LP; EMAI Management, LLC; Madison Avenue GP, LLC; Caraway Jackson Investments LLC; and Eli Samaha) and states the holdings are not intended to influence or change control of the issuer, consistent with a passive Schedule 13G filing.
The Schedule 13G/A shows that RTW Investments, LP and Roderick Wong report joint beneficial ownership of 3,055,063 shares of CARGO Therapeutics common stock, equal to 6.4% of the outstanding shares. The filing states the reported position reflects shared voting power and shared dispositive power of 3,055,063 shares and that sole voting and dispositive power are reported as zero. The percentage is calculated using 46,113,353 shares outstanding as of May 2, 2025 and assumes exercise of warrants held by the RTW Funds. RTW Investments is identified as a Delaware investment adviser and Dr. Wong as its managing partner. The filing includes a certification that the securities were acquired and are held in the ordinary course of business.
Key highlights (Q2 2025, unaudited): CARGO Therapeutics reported combined cash and marketable securities of $252.6 million and total assets of $258.6 million as of June 30, 2025. The company recorded a six‑month net loss of $134.435 million, including $83.378 million of restructuring, impairment and contract‑termination charges. Accumulated deficit was $447.1 million and total stockholders' equity was $237.7 million.
Management implemented major workforce reductions (≈50% in Jan 2025; additional actions in Mar 2025 reducing workforce by ~90% overall), discontinued the Phase 2 firi‑cel program, impaired most long‑lived assets (carried to zero except $0.5M expected sale), incurred a lease termination penalty of $35.8 million, and recorded related impairments and contract termination costs. On July 7, 2025 the company entered into a Merger Agreement with Concentra providing a $4.379 cash per‑share offer plus one CVR. The company states existing cash and securities are sufficient to support operations for at least 12 months from issuance.
FAQ
What is the current stock price of Cargo Therapeutics (CRGX)?
What is the market cap of Cargo Therapeutics (CRGX)?
